Every lot is tried & tested in a relevant biological assay.
Our Bioassay
- Fry, D. et al. (1994) Science 2665, 1093.
- Alomone Labs PD 153035 inhibits EGF receptor activation in 3T3-L1 cells.Cells were serum starved for 3 h and preincubated with different concentrations of PD 153035 (#P-360) for 2 h. The cells were then stimulated with 200 ng/ml EGF for 10 minutes. Cell proteins were resolved by SDS-PAGE and probed with anti-phospho-EGFr (upper panel) and with anti-phospho ERK1/2 (lower panel).
- Fry, D.W. et al. (1994) Science 265, 1093.
- Kunkel, M.W. et al. (1996) Invest. New Drugs 13, 295.
- Bridges, A.J. et al. (1996) J. Med. Chem. 39, 267.
- Bos, M. et al. (1997) Clin. Cancer Res. 3, 2099.
- Goossens, J.F. et al. (2001) Biochemistry 40, 4663.
- Faust, R.A. et al. (1999) Oral Oncol. 35 290.
- Kunkel, M.W. et al. (1996) Invest New Drugs, 13. 295.
- Fredriksson, A. et al. (1999) Life Sci. 65, 165.
PD 153035 is a small molecule derived from brominated anilinoquinazoline which inhibits tyrosine kinase activity of the EGFR by competition at the ATP binding site. PD 153035 is a highly potent inhibitor for auto and hetro tyrosine kinase activity of EGF receptor (ERB2) at sub nM concentrations and inhibits other purified tyrosine kinases only at micromolar or higher concentrations.1-3
PD 153053 abolished all growth effects mediated by the addition of exogenous EGF in a receptor number-dependent manner and shows a remarkable apoptotic and cytotoxic activity against several types of tumor cell lines that overexpress the EGF receptor in vitro and in vivo .4-8
PD 153035 (#P-360) is a highly pure, synthetic, and biologically active compound.
Applications
Citations
Specifications
Scientific Background
Related Products
Resources
Need Help With This Product?
Our reagent specialists are here to help you find the best product for your application. Please call or email us and we will be happy to help you find the right product for the job.
Call us at
+972 2587 2202 or Email Us